Trial | NCT00225719  Report issue

Title

Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL
Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound.

  • Phase

    Phase 2

  • Lead Sponsor

    CSL

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    180
Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient compliance due to chronicity of therapy. This study will assess the effects of rHDL compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound (IVUS) in patients after acute coronary syndromes (ACS).
Study Started
Jul 31
2005
Last Update
Nov 10
2008
Estimate

Drug rHDL

Criteria 

Inclusion Criteria:

Male or female 30 - 75 years of age
Recent acute coronary syndrome, defined as unstable angina, non-Q wave myocardial infarction, or ST elevation indicative of myocardial infarction, within the last 14 days

Exclusion Criteria:

>50% stenosis by visual angiographic estimation in the left main artery
Renal insufficiency
Severe liver disease
Congestive heart failure as defined by the NYHA classification as functional Class III or Class IV
Previous or planned coronary artery bypass surgery
No Results Posted